Our leadership team has extensive experience in developing, obtaining regulatory approvals for and successfully commercializing a variety of oncology products. In total, they have decades of combined experience spanning a range of cancers and other diseases.

Jeffrey Hanke, Ph.D.

Executive Vice President, Research and Development, and Chief Scientific Officer

Jeffrey H. Hanke, Ph.D., has served as our Executive Vice President, Research & Development, and Chief Scientific Officer since June 2015. Prior to joining TESARO, Dr. Hanke was Senior Vice President, Research and Global Head of Biotherapeutics at Boehringer Ingelheim, where he led the company's U.S. research activities and managed the biotherapeutics group. He previously served as Vice President of Cancer Research at AstraZeneca, and in several roles of increasing responsibility within the R&D organization at Pfizer. Dr. Hanke has more than twenty-five years of experience in biopharmaceutical research and development. Dr. Hanke received his doctoral degree in immunology and microbiology from Baylor College of Medicine and his master's in biology from Fordham University. He completed his post-doctoral training at the University of Texas Southwestern Medical School.